GlassScriptPhysician profile
Mithila Fadia
NPI 1144631557
$3,675.58
in general payments reported to CMS, 2019-2025
34 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.60 · 2022: $265 · 2023: $778 · 2024: $1,312 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.92 |
| Education | $102.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.12 | 2022-2025 | |
| Lundbeck LLC | $659.19 | 2022-2025 | Vyepti |
| Pfizer INC. | $393.24 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $204.44 | 2023-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $182.24 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $162.76 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Impel Pharmaceuticals LLC | $138.58 | 2024-2025 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $99.16 | 2024 | |
| Eisai INC. | $86.60 | 2024-2025 | |
| Medtronic, INC. | $82.40 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Avanir Pharmaceuticals, INC. | $78.42 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.44 | 2022 | |
| Neurelis, INC. | $76.11 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $60.79 | 2025 | Symbravo, Sunosi |
| Impel Pharmaceuticals INC. | $57.37 | 2023 | Trudhesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.46 | 2024-2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $47.33 | 2022-2024 | Austedo Xr |
| Genentech USA, INC. | $44.67 | 2024-2025 | Ocrevus |
| Biogen, INC. | $42.18 | 2025 | Leqembi |
| Averitas Pharma INC. | $39.49 | 2025 | Qutenza |
| Tg Therapeutics, INC. | $24.90 | 2024 | |
| Abbott Laboratories | $24.57 | 2025 | Eterna |
| Scilex Pharmaceuticals INC. | $23.25 | 2023 | Ztlido |
| Celgene Corporation | $21.82 | 2024 | Zeposia |
| Sumitomo Pharma America, INC. | $21.70 | 2023 | Aptiom |
| Genzyme Corporation | $20.00 | 2023 | |
| Sk Life Science, INC. | $18.03 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.81 | 2025 | Rexulti |
| Merz North America, INC. | $17.06 | 2019 | |
| Amgen INC. | $16.09 | 2022 | |
| Sonex Health, INC. | $15.76 | 2023 | Sx-One Microknife |
| Collegium Pharmaceutical, INC. | $14.99 | 2022 | |
| Emd Serono, INC. | $14.42 | 2024 | |
| Banner Life Sciences, LLC | $13.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mithila Fadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.